Cancer biotech company Sesen promotes longtime biosciences lawyer Sullivan to GC spot
Sesen Bio, a late-stage clinical company developing fusion protein therapeutics for cancer treatment , promoted it deputy general counsel, Mark Sullivan, to be its general counsel and secretary.
Sullivan (in the photo above) has more than two decades of experience in the life sciences and healthcare industries. He joined Sesen Bio in April 2018 as the acting general counsel. Before joining Sesen, he provided outsourced in-house counsel services to a variety of companies including Sandoz Inc. and Bayer Healthcare. Sullivan also has been general counsel, chief compliance officer and secretary of MModal Inc., a public healthcare IT company for 9 years, until the company was taken private by One Equity Partners in 2012. He began his career as an attorney at the law firms of Pepper Hamilton and Drinker Biddle & Reath.
“The financing in the second quarter has enabled us to build additional capabilities as we work diligently to prepare for the anticipated initiation of our BLA submission for Vicinium in the fourth quarter,” said Thomas Cannell, president and chief executive officer of Sesen Bio. “I’m delighted to have Mark to help accelerate the Company’s progress towards key milestones.”
Sullivan holds a J.D. from Rutgers University School of Law and a Bachelor of Arts from the University of Pennsylvania.